Literature DB >> 8161287

Cannabis abuse and the course of recent-onset schizophrenic disorders.

D H Linszen1, P M Dingemans, M E Lenior.   

Abstract

OBJECTIVE: We sought to examine the relation between cannabis abuse and the symptomatic course of recent-onset schizophrenia and related disorders.
DESIGN: A prospective cohort study over a year using monthly Brief Psychiatric Rating Scale assessments. PARTICIPANTS: Cannabis-abusing patients (n = 24) were compared with nonabusers (n = 69). Eleven patients were mild and 13 were heavy cannabis-abusing patients.
RESULTS: Significantly more and earlier psychotic relapses occurred in the cannabis-abusing group (P = .03). This association became stronger when mild and heavy cannabis abuse were distinguished (P = .002). No confounding effect of other variables, eg, other street drugs, was found. In all but one patient, cannabis abuse preceded the onset of the first psychotic symptoms for at least 1 year.
CONCLUSIONS: Cannabis abuse and particularly heavy abuse can be considered a stressor eliciting relapse in patients with schizophrenia and related disorders and possibly a premorbid precipitant.

Entities:  

Mesh:

Year:  1994        PMID: 8161287     DOI: 10.1001/archpsyc.1994.03950040017002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  105 in total

Review 1.  Improving the quality of the cannabis debate: defining the different domains.

Authors:  J Strang; J Witton; W Hall
Journal:  BMJ       Date:  2000-01-08

Review 2.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

3.  Remote "hovering" with individuals with psychotic disorders and substance use: feasibility, engagement, and therapeutic alliance with a text-messaging mobile interventionist.

Authors:  Dror Ben-Zeev; Susan M Kaiser; Izabela Krzos
Journal:  J Dual Diagn       Date:  2014

4.  Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.

Authors:  Serge Sevy; Delbert G Robinson; Suzanne Sunday; Barbara Napolitano; Rachel Miller; Joanne McCormack; John Kane
Journal:  Psychiatry Res       Date:  2011-06-01       Impact factor: 3.222

5.  The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe.

Authors:  Joachim Klosterkötter; Stephan Ruhrmann; Frauke Schultze-Lutter; Raimo K R Salokangas; Don Linszen; Max Birchwood; Georg Juckel; Anthony Morrison; José Luis Vázquèz-Barquero; Martin Hambrecht; Heinrich VON Reventlow
Journal:  World Psychiatry       Date:  2005-10       Impact factor: 49.548

Review 6.  Clinical staging in the pathophysiology of psychotic and affective disorders: facilitation of prognosis and treatment.

Authors:  Trevor Archer; Richard M Kostrzewa; Tomas Palomo; Richard J Beninger
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

7.  A call for standardized definition of dual diagnosis.

Authors:  Kathyrn Hryb; Rob Kirkhart; Rebecca Talbert
Journal:  Psychiatry (Edgmont)       Date:  2007-09

Review 8.  Blurred boundaries: the therapeutics and politics of medical marijuana.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

9.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

10.  A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia.

Authors:  Mary F Brunette; Ree Dawson; Christopher D O'Keefe; Meera Narasimhan; Douglas L Noordsy; Joanne Wojcik; Alan I Green
Journal:  J Dual Diagn       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.